Journal Home
Search for

Volume 14, Issue 1, Pages e41-e49 (January 2010)


View previous. 8 of 18 View next.

Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa–HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic

Helen MarshallaCorresponding Author Informationemail address, Peter McIntyreb, Don Robertona, Leonie Dinana, Karin Hardtc

Received 8 April 2008; received in revised form 25 November 2008; accepted 2 March 2009. published online 21 May 2009.

Summary 

Objectives

The aim of this study was to evaluate the safety and immunogenicity of DTPa–HBV and Hib vaccines given mixed or separately to 360 healthy infants at 2, 4, and 6 months of age.

Methods

Immune memory was assessed in lower responders (post-primary anti-PRP <0.545μg/ml), through administration of plain polyribosylribitol phosphate (PRP) at 12–15 months. All subjects received a DTPa–HBV/Hib booster at 18–19 months.

Results

One month after primary vaccination, 98% had seroprotective antibody levels against HBV and 94–97% against Hib (anti-PRP0.15μg/ml). A statistically significant difference between groups was observed in the proportion of subjects who achieved anti-PRP antibodies ≥1.0μg/ml post-primary vaccination; 68.1% for DTPa–HBV/Hib and 84.5% for DTPa–HBV and Hib. PRP administered to lower responders produced a 7-fold increase in anti-PRP antibodies, indicative of immunological memory. After DTPa–HBV/Hib booster vaccination, 96–100% of subjects had seroprotective antibody concentrations against Hib, hepatitis B, tetanus, and diphtheria and high vaccine response rates against pertussis toxoid, filamentous hemagglutinin, and pertactin.

Conclusion

A robust and protective Hib response was demonstrated following plain PRP and/or a booster conjugate Hib vaccine in both lower and higher Hib responders.

Corresponding Editor: William Cameron, Ottawa, Canada

a School of Paediatrics and Reproductive Health, University of Adelaide and Paediatric Trials Unit, Women's and Children's Hospital, Children, Youth and Women's Health Service, 72 King William Road, North Adelaide SA 5006, Australia

b National Centre for Immunisation Research and Surveillance, University of Sydney and the Children's Hospital at Westmead, New South Wales, Australia

c GlaxoSmithKline Biologicals, Rixensart, Belgium

Corresponding Author InformationCorresponding author. Tel.: +61 8 8161 8115; fax: +61 8 8161 7031.

PII: S1201-9712(09)00138-6

doi:10.1016/j.ijid.2009.03.004


View previous. 8 of 18 View next.